BPC-157, TB-500 and KPV are three peptides frequently discussed in veterinary and animal-model research. Published literature on all three includes rodent studies and, in the case of BPC-157, a canine pharmacokinetic study. This category gathers those compounds in one place for researchers comparing findings across species.
Most published research on these compounds comes from rodent models, including studies in rats and mice examining peptide distribution, metabolism, and clearance. Rodent pharmacokinetic findings do not automatically transfer to larger animals, which is why a 2022 study examining BPC-157’s pharmacokinetic and metabolic profile in rats and dogs provides a separate cross-species data point.
TB-500 appears mainly in rodent literature investigating cell migration and tissue-related signalling pathways. KPV, a fragment derived from alpha-MSH, is studied in rodent models of inflammatory pathway activity. Comparative research across species can help researchers determine which findings warrant further investigation in larger animal models.
Our BPC-157 veterinary research article provides additional detail on the canine pharmacokinetic study and cross-species research discussed above. Researchers investigating related research questions may also find our Recovery category useful.
No. Every compound in this category is sold for laboratory research only. This site does not provide dosing, administration or treatment guidance for any animal species.
Not automatically. Differences in metabolism and tissue structure between species are why the 2022 canine pharmacokinetic study on BPC-157 is treated as a separate data point from the rodent literature, not an extension of it.
Qualified researchers and laboratories conducting legitimate scientific investigations. These products are not intended for individuals seeking personal or pet-use guidance.
